Clinical trials: Anti-PD-1 Antibody
Non Small Cell Lung Cancer, Bladder Cancer
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body.
- Conditions
- Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06580938
- Testing
- PF-07921585, Sasanlimab
- Where
- 9 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
SCLC, Extensive Stage
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Phase Ib open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with chemotherapy in patients with ES-SCLC.
- Trial name
- NCT05116007
- Testing
- AK112, Etoposide, Carboplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Akeso
Multiple Myeloma
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to assess the safety of the combination of JNJ-63723283 and daratumumab (Part 1); to compare the overall response rate (ORR) in participants treated with JNJ-63723283 in combination with…
- Trial name
- NCT03357952
- Testing
- Daratumumab, JNJ-63723283
- Where
- 13 sites in Belgium, Israel and 1 more
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Thyroid Cancer
Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
The study is being conducted to evaluate the safety and efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody in subjects with advanced thyroid cancer.
- Trial name
- NCT04521348
- Testing
- multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Fudan University
Melanoma
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
The subsequent treatment choices for the patients with advanced melanoma, who have failed the immune checkpoint inhibitor therapy of single agent. Evidences showed that PD-1 and PD-L1 signalling pathways are not redundant.
- Trial name
- NCT04756934
- Testing
- HX008, LP002
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
Squamous Non-small-cell Lung Cancer
A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC
The purpose of this study is to evaluate the clinical efficacy and safety of HLX07 In Combination with HLX10 with or without Chemotherapy versus HLX10 with Chemotherapy in First Line Recurrent or Metastatic Squamous Non-Small…
- Trial name
- NCT04976647
- Testing
- HLX10+chemo, HLX10+HLX07+chemo, HLX10+HLX07
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Solid Tumor
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and…
- Trial name
- NCT04649385
- Testing
- BGB-15025, Tislelizumab, Carboplatin
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 157 people
- Sponsor
- BeiGene
Prostatic Neoplasms
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Background: Sipuleucel-T is a new treatment for advanced stage prostate cancer. It takes cells from a person with prostate cancer and treats them in the laboratory.
- Trial name
- NCT01420965
- Testing
- CT-011 (Anti-PD1 Antibody), Sipuleucel-T (Provenge), Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Augusta University
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor.
- Trial name
- NCT06563778
- Testing
- Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Esophageal Squamous Cell Carcinoma
Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma (ESCC) ,20 patients enrolled in Phase Ib PALACE-1(NCT03792347).The results…
- Trial name
- PALACE-2 (NCT04435197)
- Testing
- Pembrolizumab Injection
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- Ruijin Hospital
Advanced Solid Tumours, Cervical Cancer
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
This study is an open, multi-dose, dose escalation and cohort expansion, phase Ⅰ study to investigate the safety, tolerability, efficiency, pharmacokinetics, immunogenicity of SG001 in subjects with advanced tumours.
- Conditions
- Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma, Lymphoma
- Trial name
- NCT03852823
- Testing
- SG001
- Where
- China
- Volunteers
- 192 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Biliary Tract Cancer, PD-1 Antibody
Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
The aim of this study is to assess the R0 resection rate of tislelizumab combined with Lenvatinib and Gemox chemotherapy in the conversion therapy of potentially resectable locally advanced BTC.
- Conditions
- Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib
- Trial name
- NCT05156788
- Testing
- PD-1+Lenvatinib+GEMOX
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Neoplasms, Esophageal Diseases
Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with resectable esophageal squamous cell carcinoma
- Trial name
- NCT03200691
- Testing
- 3-DCRT or IMRT radiation, anti-PD-1 antibody SHR-1210
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Hangzhou Cancer Hospital
Metastatic Merkel Cell Carcinoma
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
- Trial name
- NCT03599713
- Testing
- Retifanlimab
- Where
- 65 sites in United States, Australia and 10 more
- Volunteers
- 107 people
- Sponsor
- Incyte Corporation
Melanoma, Unresectable Solid Tumors
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Nivolumab (and other agents affecting the anti-programmed death-1 [anti-PD-1] pathway) have demonstrated anti-tumor activity in multiple tumor types.
- Conditions
- Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type
- Trial name
- NCT04572451
- Testing
- nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Yana Najjar
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy.
- Trial name
- NCT03607890
- Testing
- Nivolumab, Relatlimab
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
The outcome of pancreatic cancer is extremely poor. NCCN guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen, but the response rate is unacceptably low.
- Trial name
- NCT03989310
- Testing
- Manganese Chloride, nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese PLA General Hospital